drrx-8k_20170109.htm

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

January 11, 2017

Date of Report

(January 9, 2017)

(Date of earliest event reported)

 

 

DURECT CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

 

 

 

 

 

 

Delaware

 

000-31615

 

94-3297098

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

10260 Bubb Road

Cupertino, CA 95014

(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Executive Officer Compensation

The following sets forth a summary of the compensation for fiscal year 2017, and bonuses awarded for fiscal year 2016, approved on January 9, 2017 by the Compensation Committee of DURECT Corporation (“the Company”) for the Company’s Chief Executive Officer, the Chief Financial Officer, and the other named executive officers of the Company for whom compensation disclosure was required in the Company’s most recent proxy statement filed with the Securities and Exchange Commission.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name and Position

  

Fiscal year
2017 Base
Salary (1)

 

  

Bonus Awarded for
Performance in 2016

 

  

Number of
Shares
subject to
annual
option
grant (3)

 

  

Target
Bonus for
Performance
in 2017
(Percentage of
Base Salary) (4)

 

  

  

Cash

 

  

Stock Options
(Number of
Shares
subject to
option
grant) (2)

 

  

  

James E. Brown, D.V.M.,

  

$

531,289

  

  

 

 

 

  

 

145,676

  

  

 

225,000

  

  

 

60

President & Chief Executive

  

  

 

 

 

  

  

  

Officer

  

  

$

0

  

  

  

  

Felix Theeuwes, D. Sc.,

  

$

316,760

  

  

 

 

 

  

 

86,854

  

  

 

168,300

  

  

 

60

Chairman & Chief Scientific

  

  

 

 

 

  

  

  

Officer

  

  

$

0

  

  

  

  

Matthew J. Hogan, Chief

  

$

355,365

  

  

 

 

 

  

 

67,148

  

  

 

112,500

  

  

 

40

Financial Officer

  

  

$

0

  

  

  

  

Judy Joice, Senior

  

$

311,428

  

  

 

 

 

  

 

53,766

  

  

 

85,500

  

  

 

35

 

%

Vice President, Operations

  

  

 

 

 

  

  

  

 & Corporate Quality

  

  

 

 

 

  

  

  

Assurance

  

  

$

0

  

  

  

  

Su Il Yum, Ph.D., Executive

  

$

123,600

  

  

 

 

 

  

 

22,516

  

  

 

36,000

  

  

 

40

Vice President, Pharmaceutical System Research and Development

  

  

$

0

  

  

  

  

 

Notes:

 

(1)

The 2017 base salary reflects no increase as compared to the base salary in 2016 for Dr. Brown and Dr. Theeuwes.  The 2017 base salary (effective April 1, 2017) reflects a 3% increase as compared to the base salary in 2016 for Mr. Hogan, Ms. Joice and Dr. Yum.

 

(2)

The bonus awarded for performance in 2016 as determined by the Compensation Committee on January 9, 2017 was established to be paid 100% in stock options. The total shares subject to each bonus option was determined by using a standard Black-Scholes option-pricing model. The exercise price per share of such option grant is $1.31, the closing price of the Company’s common stock on the NASDAQ Global Market on the date of grant. The shares subject to the bonus options are fully vested upon grant. In the event of the optionee’s termination of service with the Company for a reason other than Cause, the post termination exercise period for the options shall be one (1) year, subject to the ten (10) year term of the option.

 

(3)

The 2017 annual options were granted by the Compensation Committee on January 9, 2017. The exercise price per share of such option grant is $1.31, the closing price of the Company’s common stock on the NASDAQ Global Market on the date of grant. The vesting associated with the options is as follows: one-sixteenth (1/16) of the total shares subject to the option shall vest quarterly over four (4) years following the date of grant, subject to continued service. In the event of the optionee’s termination of service with the Company for a reason other than Cause, the post termination exercise period for the options shall be one (1) year, subject to the ten (10) year term of the option.

 

(4)

The actual bonus to be awarded will be at the Committee’s complete discretion based on the Company’s performance against specified corporate objectives and other factors to be taken into account at the discretion of the Committee.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

DURECT Corporation

 

 

 

 

Date: January 11, 2017

 

By:

 

/s/ James E. Brown

 

 

 

 

     James E. Brown

 

 

 

 

 

 

 

     President and Chief Executive Officer